Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain injury applications in Australia and internationally. The company's services include scientific consultancy, project management, data management, statistical analysis, and reporting. It operates in three segments: Clinical Trials, Academic Research, and Healthcare. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Academic Research segment offers technology and associated services to support international research studies and academic collaborations across various indications, including Alzheimer's disease, HIV, multiple sclerosis, pediatric and adult oncology, Parkinson's disease, epilepsy, and schizophrenia. As of June 30, 2018, it had participated in approximately 1,200 academic research studies in approximately 70 indications. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist in the early detection of cognitive decline. The company serves biopharmaceutical companies, sporting organizations, military, physicians and patients, academic institutions, and public-private partnerships. Cogstate Limited was founded in 1999 and is headquartered in Melbourne, Australia.
Industry, Sector and Symbol
Industry Health Information Services
Sub-IndustryN/A
SectorComputer and Technology
CIKN/A
Phone61 3 9664 1300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$26.69 million
Profitability
Miscellaneous
Employees152
Next Earnings DateN/A
OptionableNot Optionable
CogState (ASX:CGS) Frequently Asked Questions
What is CogState's stock symbol?
CogState trades on the ASX under the ticker symbol "CGS."
Has CogState been receiving favorable news coverage?
Media stories about CGS stock have been trending positive recently, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. CogState earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future. View News Stories for CogState.
Who are some of CogState's key competitors?
Some companies that are related to CogState include Kneat.com (KSI), Medadvisor (MDR), Induction Healthcare Group (INHC), Reliq Health Technologies (RHT), Vitalhub (VHI), 1ST Group (1ST), Oneview Healthcare (ONE), ICSGlobal (ICS), Diagnos (ADK), Jayex Healthcare (JHL), CardioComm Solutions (EKG), Global Health (GLH), Novita Healthcare (NHL), eWELLNESS HEALTHCARE (EWLL) and NMC Health (PMCUF).
Who are CogState's key executives?
CogState's management team includes the folowing people:
- Mr. Bradley O'Connor C.A., B.Bus, CA, CEO, MD & Exec. Director
- Dr. Paul Maruff BBSc (Hons), Ph.D., Chief Scientific Officer
- Mr. Lammert Albers, Chief Commercial Officer
- Mr. Frank Cheng, Pres of Healthcare
- Ms. Claire Newstead-Sinclair C.A., BBus, CA, Fin. Mang. & Company Sec.
How big of a company is CogState?
What is CogState's official website?
How can I contact CogState?
The company can be reached via phone at 61 3 9664 1300.
MarketBeat Community Rating for CogState (ASX CGS)
MarketBeat's community ratings are surveys of what our community members think about CogState and other stocks. Vote "Outperform" if you believe CGS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGS will underperform the S&P 500 over the long term. You may vote once every thirty days.
